# Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Dose of GV101 in Healthy Subjects

> **NCT05068947** · PHASE1 · COMPLETED · sponsor: **Graviton Bioscience Corporation** · enrollment: 16 (actual)

## Conditions studied

- Phase 1

## Interventions

- **DRUG:** GV101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05068947
- **Lead sponsor:** Graviton Bioscience Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-10
- **Primary completion:** 2021-10-22
- **Final completion:** 2021-10-22
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05068947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05068947, "Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Dose of GV101 in Healthy Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05068947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*